Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Sleep

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/sleep/zsw044PMID 28364510PMCID PMC6251695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chapter 88 – Pharmacologic Treatment of Insomnia: Other Medications

  2017cited by this paper
• Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

  2016cited by this paper
• Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians.

  2016cited by this paper
• Trends in prescribing of sedative‐hypnotic medications in the USA: 1993–2010

  2016cited by this paper
• Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis

  2016cited by this paper
• Quantitative Measures of Nocturnal Insomnia Symptoms Predict Greater Deficits Across Multiple Daytime Impairment Domains

  2015cited by this paper
• Insomnia With Physiological Hyperarousal Is Associated With Hypertension

  2015cited by this paper
• Why are benzodiazepines not yet controlled substances?

  2015cited by this paper
• Effects of cognitive behavioural therapy for insomnia on the mental health of university students: study protocol for a randomized controlled trial

  2015cited by this paper
• Cognitive Behavioral Therapy for Chronic Insomnia

  2015cited by this paper
• Insomnia increases risk for cardiovascular events in women and in men with low socioeconomic status: a longitudinal, register-based study.

  2014cited by this paper
• A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain.

  2014cited by this paper
• Insomnia as a risk factor for ill health: results from the large population‐based prospective HUNT Study in Norway

  2014cited by this paper
• The GoodNight study—online CBT for insomnia for the indicated prevention of depression: study protocol for a randomised controlled trial

  2014cited by this paper
• National use of prescription medications for insomnia: NHANES 1999-2010.

  2014cited by this paper
• Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity.

  2012cited by this paper
• Benzodiazepine use and risk of dementia: prospective population based study

  2012cited by this paper
• Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.

  2012cited by this paper
• The medicalization of sleeplessness: a public health concern.

  2011cited by this paper
• Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies.

  2011cited by this paper
• The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.

  2011cited by this paper
• Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.

  2011cited by this paper
• MSLT in primary insomnia: stability and relation to nocturnal sleep.

  2011cited by this paper
• Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.

  2011cited by this paper
• Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the A

  2011cited by this paper
• Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.

  2011cited by this paper
• Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication

  2011cited by this paper
• Patients with treatment-resistant insomnia taking nightly prescription medications for sleep: a retrospective assessment of diagnostic and treatment variables.

  2010cited by this paper
• Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial.

  2010cited by this paper
• Chapter 81 – Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists

  2010cited by this paper
• Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health and Research Diagnostic Criteria/International Classification of Sleep Disorders.

  2010cited by this paper
• Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder

  2009cited by this paper
• A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice.

  2009cited by this paper
• Characteristics of Individuals With Insomnia Who Seek Treatment in a Clinical Setting Versus Those Who Volunteer for a Randomized Controlled Trial

  2009cited by this paper
• Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference

  2009cited by this paper
• The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study.

  2009cited by this paper
• Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.

  2008cited by this paper
• Clinical guideline for the evaluation and management of chronic insomnia in adults.

  2008cited by this paper
• Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.

  2007cited by this paper
• Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.

  2007cited by this paper
• Treating insomnia: Current and investigational pharmacological approaches.

  2006cited by this paper
• Eszopiclone in Patients With Insomnia During Perimenopause and Early Postmenopause: A Randomized Controlled Trial

  2006cited by this paper
• Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

  2006cited by this paper
• NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults.

  2005cited by this paper
• NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults.

  2005influential reference
• NIH State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults statement.

  2005cited by this paper
• PNL32 PHYSICIAN AND PATIENT DETERMINANTS OF THE TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT SETTINGS IN THE UNITED STATES

  2005cited by this paper
• Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States.

  2005cited by this paper
• Self-report measures of insomnia in adults: rationales, choices, and needs.

  2004cited by this paper
• Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.

  2004cited by this paper
• Colloquy : Should Familywise Alpha Be Adjusted ? Against Familywise Alpha Adjustment

  2003cited by this paper
• Quantitative criteria for insomnia.

  2003cited by this paper
• Epidemiology of insomnia: what we know and what we still need to learn.

  2002cited by this paper
• Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.

  2001cited by this paper
• Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

  2001cited by this paper
• Zolpidem for persistent insomnia in SSRI-treated depressed patients.

  1999cited by this paper
• Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

  1999cited by this paper
• Are prescribed medications effective in the treatment of insomnia complaints?

  1999cited by this paper
• Association of road-traffic accidents with benzodiazepine use.

  1998cited by this paper
• Clinical correlates of insomnia in patients with chronic illness.

  1998cited by this paper
• Association of road-traffic accidents with benzodiazepine use.

  1998cited by this paper
• Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis.

  1996cited by this paper
• 24-Hour metabolic rate in insomniacs and matched normal sleepers.

  1995cited by this paper
• Long-term treatment of social phobia with clonazepam.

  1991cited by this paper
• The beneficial and adverse effects of hypnotics.

  1991cited by this paper
• Characteristics of individuals who do or do not seek treatment for chronic insomnia.

  1989cited by this paper
• The impact of confounder selection criteria on effect estimation.

  1989cited by this paper

• Sleep Complaints in the Psychiatric Hospital: A Qualitative Study of Nurses and Psychiatrists' Approaches to Sleep Management in a Swiss Psychiatric Hospital.

  2026cites this paper
• Sleep disorders in cancer: interactions and intrinsic links

  2025cites this paper
• Identification of five sleep-biopsychosocial profiles with specific neural signatures linking sleep variability with health, cognition, and lifestyle factors

  2025cites this paper
• Effective Dexmedetomidine Dose for Stage N2 Sleep Induction and Associated Factors in Depression-Related Insomnia: A Polysomnography-Based Analysis

  2025cites this paper
• Benzodiazepine‐receptor agonist prescription in a population of hospitalised patients in four psychogeriatric units in Switzerland

  2024cites this paper
• Prevalence of co-morbid insomnia and obstructive sleep apnoea

  2024cites this paper
• A multidimensional investigation of sleep and biopsychosocial profiles with associated neural signatures

  2024cites this paper
• A multidimensional investigation of sleep and biopsychosocialprofiles with associated neural signatures

  2024cites this paper
• Toward personalized care for insomnia in the US Army: development of a machine-learning model to predict response to pharmacotherapy

  2023cites this paper
• Prognostic models for predicting insomnia treatment outcomes: A systematic review.

  2023cites this paper
• Mindfulness-based therapy for insomnia alleviates insomnia, depression, and cognitive arousal in treatment-resistant insomnia: A single-arm telemedicine trial

  2023cites this paper
• Insomnia medications: History, characteristics, and guidelines for optimal use in clinical practice

  2023cites this paper
• Use of Sleep Aids in Insomnia: The Role of Time Monitoring Behavior.

  2023cites this paper
• Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder.

  2022cites this paper
• Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective

  2022cites this paper
• A protocol for a randomized controlled trial comparing Sleepwell, EMPOWER, and treatment-as-usual for benzodiazepine receptor agonist discontinuation in older adults: the your answers when needing sleep in New Brunswick (YAWNS NB) study

  2022cites this paper
• Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review

  2022cites this paper
• Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches

  2022cites this paper
• Effectivity of (Personalized) Cognitive Behavioral Therapy for Insomnia in Mental Health Populations and the Elderly: An Overview

  2022cites this paper
• Management of chronic insomnia using hypnotics: a friend or a foe?

  2022cites this paper
• Effect of Long-Term Benzodiazepines for Chronic Insomnia on Cognitive Function and Waking Electroencephalography: A Case-Control Study

  2022cites this paper
• Multitargeting the sleep-pain interaction with pharmacological approaches: A narrative review with suggestions on new avenues of investigation.

  2021cites this paper
• Multimodal sleep, an innovation for treating chronic insomnia: case report and literature review

  2021influential citation
• Pharmacological and non-pharmacological treatments for insomnia

  2021cites this paper
• Pneumonia Risk Associated with the Use of Individual Benzodiazepines and Benzodiazepine Related Drugs among the Elderly with Parkinson’s Disease

  2021cites this paper
• Effects of mindful breathing combined with sleep-inducing exercises in patients with insomnia

  2021cites this paper
• Pharmacologic Approach to Insomnia.

  2020cites this paper
• Recent Advances in Diagnosis and Treatment of Insomnia Disorder

  2020cites this paper
• Psychofarmaca en de behandeling van slaapstoornissen

  2020cites this paper
• Cost-effectiveness of digital CBT (Sleepio) for insomnia: A Markov simulation model in the United States.

  2020cites this paper
• Sleep disturbances in bereaved older people: a review of the literature

  2020cites this paper
• Evaluation of sedative effects of an intranasal dosage form containing saffron, lettuce seeds and sweet violet in primary chronic insomnia: A randomized, double-dummy, double-blind placebo controlled clinical trial.

  2020cites this paper
• Prevalence and management of chronic insomnia in Swiss primary care: Cross‐sectional data from the “Sentinella” practice‐based research network

  2020cites this paper
• Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey

  2019cites this paper
• Anesthesia and sleep disorders – a new problem in modern anesthesiology (literature review)

  2019cites this paper
• The acute effects of aerobic exercise on sleep in patients with depression: study protocol for a randomized controlled trial

  2019cites this paper
• Medicinal Plants for Management of Insomnia: A Systematic Review of Animal and Human Studies

  2019cites this paper
• Insomnia in patients with schizophrenia: current understanding and treatment options

  2019cites this paper
• Sleep and Orofacial Pain: Physiological Interactions and Clinical Management

  2019cites this paper
• Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation

  2019cites this paper
• Effect of ramelteon on insomnia severity: evaluation of patient characteristics affecting treatment response

  2019cites this paper
• Die insomnische Störung

  2019cites this paper
• Shift Work and Sleep: Medical Implications and Management.

  2017cites this paper
• European guideline for the diagnosis and treatment of insomnia

  2017cites this paper
• A multidimensional investigation of sleep and biopsychosocial 3 profiles with associated neural signatures 4

  year unknowncites this paper